Thought Leadership: CGRPs for Migraine Play Role in Value-Based Contracting

Despite a slew of new branded therapies for acute migraine treatment and migraine prevention, many of which target calcitonin gene-related peptide (CGRP) receptors, drug benefits experts say that health plans and PBMs continue to rely mainly on generic triptans for acute migraine treatment and generic beta-blockers, antiepileptics, and tricyclic antidepressants for migraine prevention. Precision’s Jacki Chou joins an expert discussion about developing patient-specific migraine treatment plans and the potential growth of value-based therapies.

Thought Leadership: Costs and Health Resource Use in Patients With X-linked Myotubular Myopathy: Insights From U.S. Commercial Claims

In X-linked myotubular myopathy (XLMTM), mutations in the MTM1 gene result in absence or dysfunction of myotubularin, a protein required for normal development, maintenance, and function of skeletal muscle. Extreme muscle weakness results in severe respiratory failure that is fatal for approximately half of XLMTM-affected children by age 18 months. Most surviving patients require invasive mechanical assistance as a result. Precision’s Naomi C. Sacks, Bridget Healey, and Phil Cyr look to quantify the direct medical costs and health care resource utilization incurred by XLMTM patients and paid by commercial insurers.

Thought Leadership: An Updated Cost-Utility Model for Onasemnogene Abeparvovec (Zolgensma®) in Spinal Muscular Atrophy Type 1 Patients and Comparison with Evaluation by the Institute for Clinical and Effectiveness Review (ICER)

Recent cost-utility analysis (CUA) models for onasemnogene abeparvovec (Zolgensma®, formerly AVXS-101) in spinal muscular atrophy type 1 (SMA1) differ on key assumptions and results. Precision’s Rebecca Dean, Ivar Jensen, Phil Cyr, and Beck Miller compared the manufacturer’s proprietary CUA model to the model published by ICER, to update the manufacturer’s model with long-term follow-up data and some key ICER assumptions.

Thought Leadership: Recommendations Aimed at Improving Schizophrenia Population Health Management, Care Coordination Policies

Despite therapeutic advances, managing costs while ensuring high-quality care for patients with schizophrenia continues to challenge population health decision makers (PHDMs). This unique study, conducted by Meaghan Roach, Marlon Graf, Priti Pednekar, and Jacki Chou, sought to understand PHDMs’ perceptions of challenges, policies, and programs related to schizophrenia population health management, both generally and in the context of the COVID-19 pandemic.

Read the abstract (F11):

To access the complete study, contact us today at